Towards shedding some light on regorafenib treatment in refractory metastatic colorectal cancer

被引：1
|
作者：
Prager, Gerald [1 ]
Argiles, Guillem [2 ]
机构：
[1] Med Univ Vienna, Dept Med 1, Vienna, Austria
[2] Vall d Hebron Univ Hosp, VHIO, Barcelona, Spain
来源：
ESMO OPEN | 2017年 / 2卷 / 03期
关键词：
RANDOMIZED PHASE-III; DOUBLE-BLIND; 1ST-LINE TREATMENT; BEVACIZUMAB; FLUOROURACIL; OXALIPLATIN; LEUCOVORIN; PLACEBO; TRIAL; COMBINATION;
D O I：
10.1136/esmoopen-2017-000205
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer
    Kim, Seung Tae
    Kim, Tae Won
    Kim, Kyu-Pyo
    Kim, Tae-You
    Han, Sae-Won
    Lee, Ji Yun
    Lim, Sung Hee
    Lee, Min-Young
    Kim, Haesu
    Park, Young Suk
    CANCER RESEARCH AND TREATMENT, 2015, 47 (04): : 790 - 795
  • [2] Regorafenib in the treatment of metastatic colorectal cancer
    de la Fouchardiere, Christelle
    FUTURE ONCOLOGY, 2018, 14 (22) : 2239 - 2246
  • [3] Palliative treatment of refractory metastatic colorectal cancer using regorafenib: Macau experience
    Peng, X.
    Lin, Y.
    Wang, Y.
    Hui, C.
    Lam, C.
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] Tolerance and Efficacy of Regorafenib according to UGT Pharmacogenetical Status in the Treatment of Metastatic Refractory Colorectal Cancer
    Poureau, Pierre-Guillaume
    Dhamelincourt, Estelle
    Nguyen, Jessica
    Babey, Helene
    Renaud, Emmanuelle
    Geier, Margaux
    Boisdron-Celle, Michele
    Metges, Jean-Philippe
    ONCOLOGIE, 2021, 23 (02) : 195 - 202
  • [5] Regorafenib for metastatic Colorectal Cancer?
    Bossenmayer, Susanne
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2013, 138 (12) : 563 - 563
  • [6] Regorafenib in metastatic colorectal cancer
    Sartore-Bianchi, Andrea
    Zeppellini, Annalisa
    Amatu, Alessio
    Ricotta, Riccardo
    Bencardino, Katia
    Siena, Salvatore
    EXPERT REVIEW OF ANTICANCER THERAPY, 2014, 14 (03) : 255 - 265
  • [7] The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice
    Yoon, Sang Eun
    Lee, Su Jin
    Lee, Jeeyun
    Park, Se Hoon
    Park, Joon Oh
    Lim, Ho Yeong
    Kang, Won Ki
    Park, Young Suk
    Kim, Seung Tae
    ONCOTARGETS AND THERAPY, 2019, 12 : 225 - 231
  • [8] Regorafenib for metastatic colorectal cancer
    Andre, Thierry
    Raymond, Eric
    de Gramont, Aimery
    LANCET, 2013, 381 (9877): : 1536 - 1537
  • [9] Impact of regorafenib dose optimization on comparative outcomes in the treatment of relapsed/refractory metastatic colorectal cancer (mCRC)
    Burnett, H.
    Proskorovsky, I.
    Yoon, S. S.
    Wang, Y.
    Ostojic, H.
    Gaianu, L.
    Su, Y.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S719 - S720
  • [10] EXPERIENCE WITH REGORAFENIB TREATMENT FOR METASTATIC COLORECTAL CANCER AT AICHI CANCER CENTER
    Uegaki, Shiori
    Ura, Takashi
    Tanigushi, Hiroya
    Kadowaki, Shigenori
    Takahari, Daisuke
    Andoh, Masashi
    Kato, Mina
    Tajika, Masahiro
    Muri, Kei
    ANNALS OF ONCOLOGY, 2014, 25
12345